FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind Corporation's Investigational Drug to Treat Diabetes

MannKind Corporation (Nasdaq:MNKD) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 13 to 1 to recommend that AFREZZA® (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be granted marketing approval by the FDA to improve glycemic control in adults with type 2 diabetes. If approved, AFREZZA would be the first ultra rapid-acting mealtime insulin therapy available in the United States.

Published: 02 April 2014
Written by Editor
Nasdaq   FDA HC Decision   Up on News   Interesting News  
Read more: MannKind Corporation ( MNKD )

CEL-SCI Reports March 2014 is Record Month for Patient Enrollment in Phase III Head and Neck Cancer Trial

Accelerating pace of patient enrollment driven by commitment and capabilities of new CROs and increasing number of clinical centers participating in the trial

CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of March the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global Phase III head and neck cancer trial. This marks the largest number of patients enrolled in the Company’s trial with its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in any month to date.

Published: 01 April 2014
Written by Editor
AMEX   Project Updates   Up on News   Interesting News  
Read more: CEL-SCI Corporation ( CVM )

TetraLogic Pharmaceuticals Announces Publication of Preclinical Characterization of Birinapant

TetraLogic Pharmaceuticals Corporation (TLOG) today announced that data published in the April issue of Molecular Cancer Therapeutics further advances the preclinical characterization of its lead SMAC-Mimetic birinapant, which is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors.

The publication titled "Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-{kappa}B Activation, and Is Active in Patient-Derived Xenograft Models," will appear in the April edition of Molecular Cancer Therapeutics. The electronic version of the publication is available online at http://mct.aacrjournals.org/content/early/2014/03/24/1535-7163.MCT-13-0798.abstract.

Published: 01 April 2014
Written by Editor
Nasdaq   Project Updates   Up on News   Interesting News  
Read more: TetraLogic Pharmaceuticals ( TLOG )

Triple Amputation From Flesh-Eating Disease in the United Kingdom Highlights Importance of NovaBay’s NeutroPhase Wound Cleanser

Wound care expert Dr. John Crew has pioneered a treatment using NeutroPhase that has saved the lives and limbs of the patients he’s treated

NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY). The Daily Mirror, a British newspaper, recently reported the tragic story of a father who lost both legs, an arm and half of his face to deadly flesh-eating bacteria. Alex Lewis, 34, went to bed with what he thought was a common cold, but had to be rushed to the hospital hours later in toxic shock. Doctors were barely able to save his life—and the treatment required three emergency amputations.

Published: 31 March 2014
Written by Editor
AMEX   Up on News   Interesting News  
Read more: NovaBay Pharmaceuticals Inc ( NBY )

Cynapsus Announces Interim Summary Results of Human Healthy Volunteer Single 25mg Study for APL-130277

Results Support Higher Drug Concentration in the Blood as a Result of Higher Dose Strip

Cynapsus Therapeutics Inc. (TSX VENTURE:CTH)(CYNAF), a specialty pharmaceutical company, today announced positive interim data from its recently completed healthy volunteer pilot study of a single 25mg sublingual strip (APL-130277) dose of apomorphine. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug (in the United States, Europe, Japan and other countries) to rescue patients from "off" episodes. The interim CTH-104 study results indicate that a higher load of drug on the strip does result in a higher amount of drug entering the blood stream.

Published: 28 March 2014
Written by Editor
TSX Venture   Project Updates   Up on News   Interesting News  
Read more: Cynapsus Therapeutics Inc ( CTH )
  1. Neuralstem Inc ( CUR )
  2. Idera Pharmaceuticals ( IDRA )
  3. Medicure Inc ( MPH )
  4. ProMetic Life Sciences Inc ( PLI )
  5. Galectin Therapeutics ( GALT )